The current valuation score of Indaptus Therapeutics Inc is 6.27, ranking 347 out of 387 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.24, which is -88.75% below the recent high of -0.03 and -852.14% above the recent low of -2.25.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/S
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.